{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T10:44:36Z","timestamp":1751625876405},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00120-021-01700-8","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T18:02:21Z","timestamp":1636048941000},"page":"1546-1554","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prim\u00e4r oligometastasiertes Nierenzellkarzinom\u00a0\u2013 Welchen Stellenwert hat heutzutage die Chirurgie?"],"prefix":"10.1007","volume":"60","author":[{"given":"P.","family":"Ivanyi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kuczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"1700_CR1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/annonc\/mdr362","volume":"23","author":"M Bianchi","year":"2012","unstructured":"Bianchi\u00a0M, Sun\u00a0M, Jeldres\u00a0C et al (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23:973\u2013980. https:\/\/doi.org\/10.1093\/annonc\/mdr362","journal-title":"Ann Oncol"},{"key":"1700_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ucl.2020.04.012","volume":"47","author":"B Hall","year":"2020","unstructured":"Hall\u00a0B, Abel\u00a0EJ (2020) The evolving role of metastasectomy for patients with metastatic renal cell carcinoma. Urol Clin North Am 47:379\u2013388","journal-title":"Urol Clin North Am"},{"key":"1700_CR3","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.ejso.2018.05.026","volume":"44","author":"M Sun","year":"2018","unstructured":"Sun\u00a0M, Meyer\u00a0CP, Karam\u00a0JA et\u00a0al (2018) Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. Eur J Surg Oncol 44:1439\u20131445. https:\/\/doi.org\/10.1016\/j.ejso.2018.05.026","journal-title":"Eur J Surg Oncol"},{"key":"1700_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10552-021-01435-z","volume":"32","author":"ME Hall","year":"2021","unstructured":"Hall\u00a0ME, Bhindi\u00a0B, Luckenbaugh\u00a0AN et al (2021) Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a\u00a0systematic review and meta-analysis examining effect modification according to systemic therapy approach. Cancer Causes Control 32:675\u2013680","journal-title":"Cancer Causes Control"},{"key":"1700_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.06.009","author":"A M\u00e9jean","year":"2021","unstructured":"M\u00e9jean\u00a0A, Ravaud\u00a0A, Thezenas\u00a0S et\u00a0al (2021) Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a\u00a0role for cytoreductive nephrectomy? Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2021.06.009","journal-title":"Eur Urol"},{"key":"1700_CR6","series-title":"EAU Guidelines","volume-title":"Renal cell carcinoma","author":"B Ljungberg","year":"2021","unstructured":"Ljungberg\u00a0B, Albiges\u00a0L, Bedke\u00a0J, Bex\u00a0A, Capitanio\u00a0U, Giles\u00a0RH, Hora\u00a0M, Klatte\u00a0T, Lam\u00a0T, Marconi\u00a0L, Powles\u00a0T, Volpe\u00a0A (2021) Renal cell carcinoma. EAU Annual Congress, Milan. EAU Guidelines"},{"key":"1700_CR7","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","volume":"15","author":"S Dabestani","year":"2014","unstructured":"Dabestani\u00a0S, Marconi\u00a0L, Hofmann\u00a0F et\u00a0al (2014) Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 15:e549\u2013e561","journal-title":"Lancet Oncol"},{"key":"1700_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.euo.2018.08.028","volume":"2","author":"I Ouzaid","year":"2019","unstructured":"Ouzaid\u00a0I, Capitanio\u00a0U, Staehler\u00a0M et\u00a0al (2019) Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol 2:141\u2013149","journal-title":"Eur Urol Oncol"},{"key":"1700_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/nejmoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri\u00a0TK, Powles\u00a0T, Burotto\u00a0M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N\u00a0Engl J Med 384:829\u2013841. https:\/\/doi.org\/10.1056\/nejmoa2026982","journal-title":"N Engl J Med"},{"key":"1700_CR10","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","volume":"31","author":"TK Choueiri","year":"2020","unstructured":"Choueiri\u00a0TK, Motzer\u00a0RJ, Rini\u00a0BI et al (2020) Updated efficacy results from the JAVELIN renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 31:1030\u20131039. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.010","journal-title":"Ann Oncol"},{"key":"1700_CR11","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer\u00a0RJ, Tannir\u00a0NM, McDermott\u00a0DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N\u00a0Engl J Med 378:1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"key":"1700_CR12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/nejmoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer\u00a0R, Alekseev\u00a0B, Rha\u00a0S\u2011Y et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N\u00a0Engl J Med 384:1289\u20131300. https:\/\/doi.org\/10.1056\/nejmoa2035716","journal-title":"N Engl J Med"},{"key":"1700_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.eursup.2017.09.005","volume":"16","author":"A Conti","year":"2017","unstructured":"Conti\u00a0A, D\u2019Elia\u00a0C, Cheng\u00a0M et\u00a0al (2017) Oligometastases in genitourinary tumors: recent insights and future molecular diagnostic approach. Eur Urol Suppl 16:309\u2013315. https:\/\/doi.org\/10.1016\/j.eursup.2017.09.005","journal-title":"Eur Urol Suppl"},{"key":"1700_CR14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.urolonc.2021.02.026","volume":"39","author":"PY Hsieh","year":"2021","unstructured":"Hsieh\u00a0PY, Hung\u00a0SC, Li\u00a0JR et al (2021) The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: a systematic review and meta-analysis. Urol Oncol 39:422\u2013430","journal-title":"Urol. Oncol."},{"key":"1700_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00413","author":"SH Kim","year":"2019","unstructured":"Kim\u00a0SH, Park\u00a0WS, Park\u00a0B et\u00a0al (2019) A retrospective analysis of the impact of metastasectomy on prognostic survival according to metastatic organs in patients with metastatic renal cell carcinoma. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2019.00413","journal-title":"Front Oncol"},{"key":"1700_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum\u00a0RR, Hellman\u00a0S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8:378\u2013382","journal-title":"Nat Rev Clin Oncol"},{"key":"1700_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman\u00a0S, Weichselbaum\u00a0RR (1995) Oligometastases. J\u00a0Clin Oncol 13:8\u201310","journal-title":"J Clin Oncol"},{"key":"1700_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/jjco\/hyp167","volume":"40","author":"Y Niibe","year":"2010","unstructured":"Niibe\u00a0Y, Hayakawa\u00a0K (2010) Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 40:107\u2013111","journal-title":"Jpn J Clin Oncol"},{"key":"1700_CR19","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2019.967","author":"AF Fares","year":"2019","unstructured":"Fares\u00a0AF, Araujo\u00a0DV, Calsavara\u00a0V et al (2019) Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the international metastatic RCC database consortium prognostic model. Ecancermedicalscience. https:\/\/doi.org\/10.3332\/ecancer.2019.967","journal-title":"Ecancermedicalscience"},{"key":"1700_CR20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/01.ju.0000110610.61545.ae","volume":"171","author":"RC Flanigan","year":"2004","unstructured":"Flanigan\u00a0RC, Mickisch\u00a0G, Sylvester\u00a0R et\u00a0al (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J\u00a0Urol 171:1071\u20131076. https:\/\/doi.org\/10.1097\/01.ju.0000110610.61545.ae","journal-title":"J Urol"},{"key":"1700_CR21","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1002\/ijc.28553","volume":"134","author":"SL Conti","year":"2014","unstructured":"Conti\u00a0SL, Thomas\u00a0IC, Hagedorn\u00a0JC et\u00a0al (2014) Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer 134:2245\u20132252. https:\/\/doi.org\/10.1002\/ijc.28553","journal-title":"Int J Cancer"},{"key":"1700_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.clgc.2016.04.001","volume":"14","author":"F Petrelli","year":"2016","unstructured":"Petrelli\u00a0F, Coinu\u00a0A, Vavassori\u00a0I et al (2016) Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a\u00a0meta-analysis. Clin Genitourin Cancer 14:465\u2013472","journal-title":"Clin Genitourin Cancer"},{"key":"1700_CR23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.eururo.2014.05.034","volume":"66","author":"DYC Heng","year":"2014","unstructured":"Heng\u00a0DYC, Wells\u00a0JC, Rini\u00a0BI et\u00a0al (2014) Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur Urol 66:704\u2013710. https:\/\/doi.org\/10.1016\/j.eururo.2014.05.034","journal-title":"Eur Urol"},{"key":"1700_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.eururo.2019.06.006","volume":"76","author":"RE De Bruijn","year":"2019","unstructured":"De Bruijn\u00a0RE, Mulders\u00a0P, Jewett\u00a0MA et\u00a0al (2019) Surgical safety of cytoreductive nephrectomy following sunitinib: results from the multicentre, randomised controlled trial of immediate versus deferred nephrectomy (SURTIME). Eur Urol 76:437\u2013440. https:\/\/doi.org\/10.1016\/j.eururo.2019.06.006","journal-title":"Eur Urol"},{"key":"1700_CR25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00345-015-1707-0","volume":"34","author":"P Ivanyi","year":"2016","unstructured":"Ivanyi\u00a0P, Koenig\u00a0J, Trummer\u00a0A et al (2016) Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival? World J Urol 34:909\u2013915. https:\/\/doi.org\/10.1007\/s00345-015-1707-0","journal-title":"World J Urol"},{"key":"1700_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijsu.2017.03.062","volume":"41","author":"Y Zhao","year":"2017","unstructured":"Zhao\u00a0Y, Li\u00a0J, Li\u00a0C et al (2017) Prognostic factors for overall survival after lung metastasectomy in renal cell cancer patients: a systematic review and meta-analysis. Int J Surg 41:70\u201377","journal-title":"Int J Surg"},{"key":"1700_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/14737140.2020.1770601","volume":"20","author":"M Donini","year":"2020","unstructured":"Donini\u00a0M, Buti\u00a0S, Massari\u00a0F et\u00a0al (2020) Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. Expert Rev Anticancer Ther 20:491\u2013501","journal-title":"Expert Rev Anticancer Ther"},{"key":"1700_CR28","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.2217\/fon-2017-0175","volume":"13","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman\u00a0O (2017) Clinical correlates and prognostic value of different metastatic sites in metastatic renal cell carcinoma. Future Oncol 13:1967\u20131980. https:\/\/doi.org\/10.2217\/fon-2017-0175","journal-title":"Future Oncol."},{"key":"1700_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.clgc.2013.04.012","volume":"11","author":"MM Vickers","year":"2013","unstructured":"Vickers\u00a0MM, Al-Harbi\u00a0H, Choueiri\u00a0TK et al (2013) Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 11:311\u2013315. https:\/\/doi.org\/10.1016\/j.clgc.2013.04.012","journal-title":"Clin Genitourin Cancer"},{"key":"1700_CR30","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0360-3016(00)00804-X","volume":"48","author":"H Ikushima","year":"2000","unstructured":"Ikushima\u00a0H, Tokuuye\u00a0K, Sumi\u00a0M et\u00a0al (2000) Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 48:1389\u20131393. https:\/\/doi.org\/10.1016\/S0360-3016(00)00804-X","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1700_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-021-02925-y","author":"A Bibok","year":"2021","unstructured":"Bibok\u00a0A, Mhaskar\u00a0R, Jain\u00a0R et al (2021) Role of radioembolization in the management of liver-dominant metastatic renal cell carcinoma: a single-center, retrospective study. Cardiovasc Intervent Radiol. https:\/\/doi.org\/10.1007\/s00270-021-02925-y","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1700_CR32","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07258-2","author":"Q Huang","year":"2019","unstructured":"Huang\u00a0Q, Zhou\u00a0H, Liu\u00a0C et al (2019) Surgical resection for metastatic tumors in the pancreas: a single-center experience and systematic review. Ann Surg Oncol. https:\/\/doi.org\/10.1245\/s10434-019-07258-2","journal-title":"Ann Surg Oncol"},{"key":"1700_CR33","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.3390\/jcm9103278","volume":"9","author":"AC Milanetto","year":"2020","unstructured":"Milanetto\u00a0AC, Morelli\u00a0L, Di Franco\u00a0G et\u00a0al (2020) A plea for surgery in pancreatic metastases from renal cell carcinoma: indications and outcome from a\u00a0multicenter surgical experience. J\u00a0Clin Med 9:3278. https:\/\/doi.org\/10.3390\/jcm9103278","journal-title":"J Clin Med"},{"key":"1700_CR34","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11605-013-2278-2","volume":"18","author":"JJ Tosoian","year":"2014","unstructured":"Tosoian\u00a0JJ, Cameron\u00a0JL, Allaf\u00a0ME et\u00a0al (2014) Resection of isolated renal cell carcinoma metastases of the pancreas: outcomes from the Johns Hopkins hospital. J\u00a0Gastrointest Surg 18:542\u2013548. https:\/\/doi.org\/10.1007\/s11605-013-2278-2","journal-title":"J Gastrointest Surg"},{"key":"1700_CR35","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1245\/s10434-014-4256-7","volume":"22","author":"M Santoni","year":"2015","unstructured":"Santoni\u00a0M, Conti\u00a0A, Partelli\u00a0S et\u00a0al (2015) Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol 22:2094\u20132100. https:\/\/doi.org\/10.1245\/s10434-014-4256-7","journal-title":"Ann Surg Oncol"},{"key":"1700_CR36","first-page":"2","volume":"22","author":"J Bauml","year":"2018","unstructured":"Bauml\u00a0J (2018) Oligometastatic disease in cancer. Broadening the path to cure? Int J Target Ther Cancer 22:2","journal-title":"Int J Target Ther Cancer"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01700-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-021-01700-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01700-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T14:04:57Z","timestamp":1638972297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-021-01700-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1700"],"URL":"https:\/\/doi.org\/10.1007\/s00120-021-01700-8","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"7 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0Ivanyi: Honorare und Berater und Studient\u00e4tigkeit: BMS, Ipsen, Bayer, EUSA, EISAI, ROCHE, Merck Serono. MSD. M.\u00a0Kuczyk gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}